Imagine two people with the same advanced lung cancer diagnosis. One gets a precise test that unlocks a targeted therapy. The other doesn't. Their chances start to diverge based on geography and income before treatment even begins. A new global review confirms this is still the harsh reality for many. It finds that access to modern molecular diagnostics and newer treatments like immunotherapy remains highly uneven across different countries and healthcare systems. This isn't about one new drug; it's about the entire pathway of care, from getting an accurate genetic profile of the tumor to having the right medicine available and affordable.
The review looked at the situation for patients with advanced non-small cell lung cancer around the world. It didn't involve new patients or run new trials. Instead, it pulled together existing evidence from guidelines and real-world reports to paint a clear picture of these persistent disparities. The core finding is straightforward: where you are and what you can afford still heavily influence whether you can get the most advanced care.
It's important to understand what this review can and cannot tell us. It powerfully describes the problem and the factors that contribute to it, like regional differences in healthcare infrastructure. However, it doesn't provide new numbers on how many patients are affected or quantify exactly how much these disparities shorten lives. It synthesizes what we already know to underscore that the promise of personalized medicine is not yet a global reality. The call here isn't for a new pill, but for a more equitable system.